Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: November 2025 (Event date: November 18, 2025; Filing date: November 21, 2025)
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific corporate action regarding warrant terms.
Material Changes
On November 18, 2025, the Company entered into an agreement with the holder of warrants to purchase 16,666,666 American Depositary Shares (ADSs) previously issued on July 29, 2025. Key terms of the change include:
- Exercise Price Reduction: The exercise price was reduced from $0.60 per ADS to $0.467 per ADS.
- Consideration: The price reduction was granted in consideration for the holder's waiver of certain standstill provisions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items beyond the warrant modification described above.
Investor Verification Checklist
- Verify the total dilution impact of the 16,666,666 warrants at the new exercise price of $0.467.
- Review the specific "standstill provisions" waived by the warrant holder to understand potential changes in shareholder rights or governance.
- Confirm the current cash position of the Company to assess its ability to fund operations without immediate reliance on warrant exercises.